Hereditary Angioedema Therapeutic Market Analysis Report By Drug Class (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor), By Route of Administration, By Treatment Type, And Segment Forecasts, 2019 - 2026

Published: Jul, 2019 | Pages: 100 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global hereditary angioedema therapeutic market size is expected to reach USD 4.2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting an 8.1% CAGR during the forecast period. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China's National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

Further key findings from the report suggest:

• The C1-esterase inhibitor segment held the largest share in 2018 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE

• On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment

• Based on route of administration, intravenous drug therapies was one of the largest segments. Subcutaneously-administered therapies, on the other hand, are estimated to exhibit a lucrative CAGR of over 9.0% during the forecast period owing to benefits such as convenient dosing and improved drug effectiveness

• North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2018. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market

• Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region

• Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.

 Table of Contents

Chapter 1. Methodology and Scope
                  1.1. Market segmentation & scope
                  1.2. Market definition
                  1.3. Information procurement
                      1.3.1. Purchased database
                      1.3.2. GVR's internal database
                      1.3.3. Secondary sources & third party perspectives
                      1.3.4. Primary research
                  1.4. Information analysis
                      1.4.1. Data analysis models
                  1.5. Market formulation & data visualization
                  1.6. Data validation & publishing

Chapter 2. Executive Summary
                  2.1. Market Outlook 
                  2.2. Segment Outlook 
                  2.3. Competitive Insights

Chapter 3. Global Hereditary Angioedema Therapeutics Market Variables, Trends & Scope
                  3.1. Hereditary Angioedema Therapeutics: Product Pipeline Analysis
                  3.2. Market Dynamics
                      3.2.1. Market Driver Analysis
                      3.2.2. Market Restraint Analysis
                  3.3. Hereditary Angioedema Therapeutics Market Analysis Tools
                      3.3.1. Industry Analysis - Porter's
                          3.3.1.1. Supplier Power: Moderate 
                          3.3.1.2. Buyer Power: Moderate
                          3.3.1.3. Substitution Threat: Low
                          3.3.1.4. Threat from new entrant: Low
                          3.3.1.5. Competitive rivalry: High 
                  3.4. PESTEL Analysis
                      3.4.1. Political Landscape
                      3.4.2. Environmental Landscape
                      3.4.3. Social Landscape
                      3.4.4. Technology Landscape
                      3.4.5. Legal Landscape

Chapter 4. Hereditary Angioedema Therapeutics Market: Drug Class Estimates & Trend Analysis 
                  4.1. Definitions & Scope 
                  4.2. Drug Class market share analysis, 2018 & 2026
                  4.3. Global Hereditary Angioedema Therapeutics Market, by Drug Class, 2014 to 2026
                  4.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following:
                  4.5. C1-esterase inhibitor 
                      4.5.1. C1-esterase inhibitor market, 2014 - 2026 (USD Million)
                  4.6. Bradykinin B2 receptor antagonist
                      4.6.1. Bradykinin B2 receptor antagonist market, 2014 - 2026 (USD Million)
                  4.7. Kallikrein inhibitor
                      4.7.1. Kallikrein inhibitor market, 2014 - 2026 (USD Million)
                  4.8. Others
                      4.8.1. Others market, 2014 - 2026 (USD Million)

Chapter 5. Hereditary Angioedema Therapeutics Market: Treatment Type Estimates & Trend Analysis 
                  5.1. Definitions & Scope 
                  5.2. Treatment Type market share analysis, 2018 & 2026
                  5.3. Global Hereditary Angioedema Therapeutics Market, by Treatment Type, 2014 to 2026
                  5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                  5.5. Prophylaxis treatment
                      5.5.1. Prophylaxis treatment market, 2014 - 2026 (USD Million)
                  5.6. On-demand treatment
                      5.6.1. On-demand treatment market, 2014 - 2026 (USD Million)

Chapter 6. Hereditary Angioedema Therapeutics Market: Route of Administration Estimates & Trend Analysis 
                  6.1. Definitions & Scope 
                  6.2. Route of Administration market share analysis, 2018 & 2026
                  6.3. Global Hereditary Angioedema Therapeutics Market, by Route of Administration, 2014 to 2026
                  6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                  6.5. Intravenous
                      6.5.1. Intravenous market, 2014 - 2026 (USD Million)
                  6.6. Subcutaneous
                      6.6.1. Subcutaneous market, 2014 - 2026 (USD Million)
                  6.7. Oral
                      6.7.1. Oral market, 2014 - 2026 (USD Million)

Chapter 7. Hereditary Angioedema Therapeutics Market: Regional Estimates & Trend analysis, by Drug Class, Treatment Type & Route of Administration
                  7.1. Regional Market Snapshot 
                  7.2. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
                      7.2.1. North America 
                      7.2.2. Europe
                      7.2.3. Asia Pacific
                      7.2.4. Latin America
                      7.2.5. Middle East & Africa
                  7.3. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
                  7.4. North America
                      7.4.1. North America Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million) 
                      7.4.2. U.S.
                          7.4.2.1. U.S. Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.4.3. Canada
                          7.4.3.1. Canada Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                  7.5. Europe
                      7.5.1. Europe Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million) 
                      7.5.2. U.K.
                          7.5.2.1. U.K. Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.5.3. Germany
                          7.5.3.1. Germany Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.5.4. Spain
                          7.5.4.1. Spain Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.5.5. France
                          7.5.5.1. France Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.5.6. Italy
                          7.5.6.1. Italy Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.5.7. Russia
                          7.5.7.1. Russia Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                  7.6. Asia Pacific
                      7.6.1. Asia Pacific Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million) 
                      7.6.2. China
                          7.6.2.1. China Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.6.3. Japan
                          7.6.3.1. Japan Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.6.4. India
                          7.6.4.1. India Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.6.5. South Korea
                          7.6.5.1. South Korea Hereditary Angioedema Therapeutics Market, 2014 -2026 (USD Million)
                      7.6.6. Singapore
                          7.6.6.1. Singapore Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.6.7. Australia
                          7.6.7.1. Australia Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                  7.7. Latin America
                      7.7.1. Latin America Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million) 
                      7.7.2. Brazil
                          7.7.2.1. Brazil Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.7.3. Mexico
                          7.7.3.1. Mexico Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.7.4. Argentina
                          7.7.4.1. Argentina Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                  7.8. MEA
                      7.8.1. MEA Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million) 
                      7.8.2. Israel
                          7.8.2.1. Israel Hereditary Angioedema Therapeutics market, 2014 - 2026 (USD Million)
                      7.8.3. Saudi Arabia
                          7.8.3.1. Saudi Arabia Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)
                      7.8.4. UAE
                          7.8.4.1. UAE Hereditary Angioedema Therapeutics Market, 2014 - 2026 (USD Million)

Chapter 8. Company Profiles
                  8.1. Strategic Framework
                      8.1.1. Shire Plc
                          8.1.1.1. Company overview
                          8.1.1.2. Financial framework
                          8.1.1.3. Product benchmarking
                          8.1.1.4. Strategic initiatives
                      8.1.2. BioCryst Pharmaceuticals, Inc.
                          8.1.2.1. Company overview
                          8.1.2.2. Financial framework
                          8.1.2.3. Product benchmarking
                          8.1.2.4. Strategic initiatives
                      8.1.3. Ionis Pharmaceuticals, Inc.
                          8.1.3.1. Company overview
                          8.1.3.2. Financial framework
                          8.1.3.3. Product benchmarking
                          8.1.3.4. Strategic initiatives
                      8.1.4. Pharming Group N.V.
                          8.1.4.1. Company overview
                          8.1.4.2. Financial framework
                          8.1.4.3. Product benchmarking
                          8.1.4.4. Strategic initiatives
                      8.1.5. CSL Limited
                          8.1.5.1. Company overview
                          8.1.5.2. Financial framework
                          8.1.5.3. Product benchmarking
                          8.1.5.4. Strategic initiatives
                      8.1.6. Attune Pharmaceuticals, Inc.
                          8.1.6.1. Company overview
                          8.1.6.2. Financial framework
                          8.1.6.3. Product benchmarking
                          8.1.6.4. Strategic initiatives
                      8.1.7. Adverum Biotechnologies, Inc.
                          8.1.7.1. Company overview
                          8.1.7.2. Financial framework
                          8.1.7.3. Product benchmarking
                          8.1.7.4. Strategic initiatives
                      8.1.8. KalVista Pharmaceuticals, Inc.
                          8.1.8.1. Company overview
                          8.1.8.2. Financial framework
                          8.1.8.3. Product benchmarking
                          8.1.8.4. Strategic initiatives

List of Tables

TABLE 1 List of Abbreviation
TABLE 2 North America hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 3 North America hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 4 North America hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 5 U.S. hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 6 U.S. hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 7 U.S. hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 8 Canada hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 9 Canada hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 10 Canada hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 11 Europe hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 12 Europe hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 13 Europe hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 14 Germany hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 15 Germany Hereditary Angioedema Therapeutics Market, by treatment type, 2014 - 2026 (USD Million)
TABLE 16 Germany hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 17 France hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 18 France hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 19 France hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 20 U.K. hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 21 U.K. hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 22 U.K. hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 23 Italy hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 24 Italy hereditary angioedema therapeutics market, by treatment rype, 2014 - 2026 (USD Million)
TABLE 25 Italy hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 26 Spain hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 27 Spain hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 28 Spain hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 29 Russia hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 30 Russia hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 31 Russia hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 32 Asia Pacific hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 33 Asia Pacific hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 34 Asia Pacific hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 35 Japan hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 36 Japan hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 37 Japan hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 38 China hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 39 China hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 40 China hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 41 India hereditary angioedema therapeutics market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 42 India hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 43 India hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 44 South Korea hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 45 South Korea hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 46 South Korea hereditary angioedema therapeutics market, by Route of Administration, 2014 - 2026 (USD Million)
TABLE 47 Australia hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 48 Australia hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 49 Australia hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 50 Singapore hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 51 Singapore hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 52 Singapore hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 53 Latin America hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 54 Latin America hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 55 Latin America hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 56 Brazil hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 57 Brazil hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 58 Brazil hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 59 Mexico hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 60 Mexico hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 61 Mexico hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 62 Argentina hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 63 Argentina hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 64 Argentina hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 65 MEA hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 66 MEA hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 67 MEA hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 68 Israel hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 69 Israel hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 70 Israel hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 71 Saudi Arabia hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 72 Saudi Arabia hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 73 Saudi Arabia hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)
TABLE 74 UAE hereditary angioedema therapeutics market, by drug class, 2014 - 2026 (USD Million)
TABLE 75 UAE hereditary angioedema therapeutics market, by treatment type, 2014 - 2026 (USD Million)
TABLE 76 UAE hereditary angioedema therapeutics market, by route of administration, 2014 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global hereditary angioedema therapeutics - Key market driver analysis
FIG. 7 Global hereditary angioedema therapeutics market - Key market restraint analysis
FIG. 8 Global hereditary angioedema therapeutics market - Porter's analysis
FIG. 9 Global hereditary angioedema therapeutics market - PESTEL analysis
FIG. 10 Global hereditary angioedema therapeutics market: Drug class outlook key takeaways
FIG. 11 Global hereditary angioedema therapeutics market: Drug class movement analysis
FIG. 12 Drug class market estimates, 2014 - 2026 (USD Million)
FIG. 13 C1-esterase inhibitor market estimates, 2014 - 2026 (USD Million)
FIG. 14 Bradykinin B2 receptor antagonist market estimates, 2014 - 2026 (USD Million)
FIG. 15 Kallikrein inhibitor market estimates, 2014 - 2026 (USD Million)
FIG. 16 Other drug market estimates, 2014 - 2026 (USD Million)
FIG. 17 Global hereditary angioedema therapeutics market: Treatment Type outlook key takeaways
FIG. 18 Global hereditary angioedema therapeutics market: Treatment type movement analysis
FIG. 19 Treatment type market estimates, 2014 - 2026 (USD Million)
FIG. 20 Prophylaxis market estimates, 2014 - 2026 (USD Million)
FIG. 21 On-demand market estimates, 2014 - 2026 (USD Million)
FIG. 22 Global hereditary angioedema therapeutics market: Route of administration outlook key takeaways
FIG. 23 Global hereditary angioedema therapeutics market: Route of administration movement analysis
FIG. 24 Route of administration market estimates, 2014 - 2026 (USD Million)
FIG. 25 Intravenous market estimates, 2014 - 2026 (USD Million)
FIG. 26 Subcutaneous market estimates, 2014 - 2026 (USD Million)
FIG. 27 Oral market estimates, 2014 - 2026 (USD Million)
FIG. 28 Global hereditary angioedema therapeutics regional market place: Key takeaways
FIG. 29 Global hereditary angioedema therapeutics market: Regional movement analysis
FIG. 30 North America hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 31 U.S. hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 32 Canada hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 33 Europe hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 34 Germany hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 35 France hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 36 U.K. hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 37 Italy hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 38 Spain hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 39 Russia hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 40 Asia Pacific hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 41 Japan hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 42 China hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 43 India hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 44 South Korea hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 45 Australia hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 46 Singapore hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 47 Latin America hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 48 Brazil hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 49 Mexico hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 50 Argentina hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 51 MEA hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 52 Israel hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 53 Saudi Arabia hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)
FIG. 54 UAE hereditary angioedema therapeutics market, 2014 - 2026 (USD Million)